



# INJECTION TECHNIQUE

# IS IT IMPORTANT?

© Healthwise, Incorporated

**Anders Frid, MD, PhD, Copenhagen**  
**October 2014**







# Injection Technique: What Do We Know and What Do We Want to Know?

- What about insulin absorption from different sites? Are modern insulin analogues different from human insulins regarding absorption?
- In what tissue do we want to deposit insulin?
- What technique do we use to achieve that?
- Does depth of injection influence absorption?
- How thick is the skin?



# Injection Technique: What Do We Know and What Do We Want to Know?

- What about insulin absorption from different sites? Are modern insulin analogues different from human insulins regarding absorption?
- In what tissue do we want to deposit insulin?
- What technique do we use to achieve that?
- Does depth of injection influence absorption?
- How thick is the skin?



# Christian Binder 1969:

- Soluble  $^{131}\text{I}$ -insulin (pig, U40) is absorbed faster from the abdomen compared to thigh with buttock in between.

C. Binder: Absorption of injected insulin. Thesis, Copenhagen 1969



# NPH insulin

- Henriksen et al: Absorption of NPH (isophane) insulin in resting diabetic patients: evidence for subcutaneous injection in the thigh as the preferred site.

Diabet Med. 1991 Jun;8(5):453-7.





# Absorption of Rapid-Acting Insulin Analogs

- No statistically significant difference between abdomen and thigh in time-to-peak.
- Peak is somewhat lower and effect more protracted in thigh.




# Absorption of regular insulin and insulin lispro<sup>2</sup>

Mean GIR versus time of all treatments (n = 12): Regular insulin (0.2 U/kg; A, insulin lispro (0.2 U/kg; B).



## Absorption of insulin $^{125}\text{I}$ -glargine after injection in arm, thigh and abdominal area



- \_\_\_\_\_ = arm


- ..... = thigh

- ----- = abdomen


Owens et al, Diabetes Care 23;6, June 2000




# Insulin Levemir




# Insulin Levemir







## Injection site:



# Injection site: ?




## Injection site: ? Abdomen (pers. mess.)



Insulin Levemir


Injection site:



Plank et al. *Diabetes Care* 28:1107–1112, 2005



## Injection site: thigh



# Injection Technique: What Do We Know and What Do We Want to Know?

- What about insulin absorption from different sites? Are modern insulin analogues different from human insulins regarding absorption?
- In what tissue do we want to deposit insulin?
- What technique do we use to achieve that?
- Does depth of injection influence absorption?
- How thick is the skin?



# Effect of intramuscular injection, regular human insulin





Fig 10. Plasma immunoactive insulin following injection of  $^{125}$ I-labelled soluble insulin (Actrapid H 40U; 10U) in muscle (solid line) and fat (dashed line) tissue in 10 IDDM patients. Bicycle exercise is indicated between bars.




# Absorption of Rapid-Acting Insulin Analogs

- No statistically significant difference in insulin absorption between fat and muscle tissue; however, only studied in resting muscle
- There is a 10-fold increase in blood flow in the working muscle!
- International consensus is still to recommend subcutaneous (sc), ie, intralipomatous injection



# Insulin detemir, sc and im injection



Novo Nordisk data on file

Trial ID.: NN3041320  
 Each mean profile based on data from 16 subjects  
 Note that at least two measurements must be available to calculate a mean concentration of Insulin Detemir. Thus at time points where there is one or no valid measurements no markings occur on the figure e.g. at time points later than 240 minutes for the i.v. adm. route

Spadille ApS (08FEB02)



**IDM**


# **Early hypoglycaemia after accidental intramuscular injection of insulin glargine**

B. Karges, B. O. Boehm\* and W. Karges\*

Diabetic Medicine 2005;22:1444-45




# CT of thigh, normal-weight adult male



CT scan of abdomen, normal-weight male. White dots are contrast. 8 mm needle.



CT, abdominal area, female with DM2, BMI 28.0



# Some Observations of Human Fat Tissue Distribution

## Adult females

- Many have less than 8 mm of fat tissue laterally in the thigh
- All have more than 12 mm of fat tissue in the gluteal area
- Some may have less than 5 mm of fat tissue laterally in the abdominal area

## Adult males

- A majority have less than 5 mm of fat tissue laterally in the thigh
- All have more than 12 mm of fat tissue in the gluteal area
- Many have less than 5 mm of fat tissue laterally in the abdominal area





# Injection Technique: What Do We Know and What Do We Want to Know?

- What about insulin absorption from different sites? Are modern insulin analogues different from human insulins regarding absorption?
- In what tissue do we want to deposit insulin?
- What technique do we use to achieve that?
- Does depth of injection influence absorption?
- How thick is the skin?



# CT of thigh, normal-weight adult male






# Injection Technique: What Do We Know and What Do We Want to Know?

- What about insulin absorption from different sites? Are modern insulin analogues different from human insulins regarding absorption?
- In what tissue do we want to deposit insulin?
- What technique do we use to achieve that?
- Does depth of injection influence absorption?
- How thick is the skin?




# Injection Depth and Insulin Absorption



Frid et al., Intraregional Differences in the Absorption of Unmodified Insulin from the Abdominal Wall.  
Diabetic Medicine 1992; 9; 236-239




# Injection Depth and Insulin Absorption



- $^{125}\text{I}$ -labelled short acting insulin was injected ( 5 units each patient)
- Radioactivity decreased by insulin absorption (in %)
- One defined injection site was chosen for each abdomen and thigh
- 2 injection depths, controlled by ultrasound:

**A) 3mm below the skin surface**

**B) 2mm above the muscle facies**



Injection Depth B) [from skin surface in mm]:


Abdomen    ♂  $9 \pm 2$  / ♀  $15 \pm 3$

Thigh       ♂  $7 \pm 1$  / ♀  $14 \pm 3$

Frid et al., Intraregional Differences in the Absorption of Unmodified Insulin from the Abdominal Wall\_Diabetic Medicine 1992; 9; 236-239



# Injection Depth and Insulin Absorption



**No influence of the injection depth on the kinetics of insulin absorption has been shown in the study.**



# **Influence of needle size for subcutaneous insulin administration on metabolic control and patient acceptance**

*G Kreugel,\* HJM Beijer, MN Kerstens, JC ter Maaten, WJ Sluiter, BS Boot*

Eur Diabetes Nursing 2007;4(2):1-5



**Conclusion:** For insulin injection, a 5mm needle length is associated with unchanged HbA<sub>1c</sub> levels, unchanged frequency or severity of hypoglycaemic events and less discomfort for patients compared with 8 or 12 mm needles. The use of 5 mm needles is as safe as 8 or 12 mm needles. Further research is advisable involving thin and obese patients using 5 mm needles, in order for shorter needles to be recommended as standard practice.

Eur Diabetes Nursing 2007;4(2):1-5



# Injection Technique: What Do We Know and What Do We Want to Know?

- What about insulin absorption from different sites? Are modern insulin analogues different from human insulins regarding absorption?
- In what tissue do we want to deposit insulin?
- What technique do we use to achieve that?
- Does depth of injection influence absorption?
- How thick is the skin?



Gibney MA et al. Curr Med Res Opin. 2010  
Jun;26(6):1519-30


## Original article

# Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations


---

Michael A. Gibney  
Christina H. Arce  
Karen J. Byron  
Laurence J. Hirsch

BD (Becton, Dickinson and Company), Franklin Lakes,  
NJ, USA



Gibney MA et al. Curr Med Res Opin. 2010 Jun;26(6):1519-30



# What Insulins at What Injection Site?

- All insulins should normally be given sc
- Soluble human insulins in the abdominal area
- NPH-insulins in the thigh or gluteal area
- Rapid-acting insulin analogs in the abdomen, may be given elsewhere
- Insulin glargine in abdomen, thigh, or gluteal area (no studies), strictly sc
- Insulin detemir in the thigh (or gluteal area, no studies), strictly sc
- Premix insulins abdominal area in the morning; thigh or gluteal area in the afternoon/evening




# So what about GLP-1 analogs?

- Calara F et al: ...all injection sites yielded equivalent pharmacokinetic profiles strongly suggesting equivalent **exenatide** bioavailability after subcutaneous injection into the arm, thigh, or abdomen.


**Clin Ther.** 2005 Feb;27(2):210-5.




Kapitza et al:




*Journal of Clinical Pharmacology*, 2011;51:951-955



Kapitza et al:



*Journal of Clinical Pharmacology, 2011;51:951-955*



# INJECTION TECHNIQUE

## IS IT IMPORTANT?

© Healthwise, Incorporated





**INJECTION TECHNIQUE  
OF COURSE IT IS!**



**IS IT IMPORTANT?**

© Healthwise, Incorporated



# TITAN

127 participants from Europe, Russia, USA, Canada, China, Taiwan, South Korea, Japan, Indonesia, The Philippines, India and Pakistan

10<sup>th</sup> - 13<sup>th</sup> September 2009

**T.I.T.A.N**

Third Injection Technique  
workshop in AtheNs



## New injection recommendations for patients with diabetes

A. Frid<sup>a</sup>, L. Hirsch<sup>b</sup>, R. Gaspar<sup>c</sup>, D. Hicks<sup>d</sup>, G. Kreugel<sup>e</sup>, J. Liersch<sup>f</sup>, C. Letondeur<sup>g</sup>,

J.P. Sauvanet<sup>h</sup>, N. Tubiana-Rufi<sup>i</sup>, K. Strauss<sup>j,\*</sup>

<sup>a</sup> Endocrinologist, Clinic of Endocrinology, Skåne University Hospital, Malmö, Sweden

<sup>b</sup> Endocrinologist, Worldwide VP Medical Affairs, BD Diabetes Care, Franklin Lakes, New Jersey, USA

<sup>c</sup> Diabetes Specialty Nurse, Diabetes Unit, University Hospital La Paz, Madrid, Spain

<sup>d</sup> Diabetes Specialty Nurse, Diabetes Service, NHS Enfield Community Services, London, UK

<sup>e</sup> Diabetes Specialty Nurse, Diabetes Unit, University Medical Center Groningen, The Netherlands

<sup>f</sup> Diabetes Specialty Nurse, Diabetes-Schulungszentrum, Universitätsklinikum Giessen und Marburg, Germany

<sup>g</sup> Diabetes Education Manager, BD Diabetes Care, Rungis, France

<sup>h</sup> Endocrinologist, Internal Medicine Department, APHP Hôpital Saint-Louis, Paris, France

<sup>i</sup> Pediatric Endocrinologist, Diabetes Department, APHP Hôpital Robert Debré, Paris, France

<sup>j</sup> Endocrinologist, Global Medical Director, BD Diabetes Care, Erembodegem, Belgium

# Needle length

- 4, 5 and 6 mm needles may be used by any patient including obese ones; they will provide equivalent glycaemic control compared to 8 mm and 12.7 mm needles (9,63,110,112,113) A1
- There is no evidence to date of significant leakage of insulin, increased pain, worsened diabetes management or other complications whrn using shorter (5-6 mm) needles. (9,63,110,114) A1



# Lifting a skin fold

- Skin folds are essential when the distance from skin surface to the muscle is less than the length of the needle
- Lifting a skin fold is an easy and effective means for ensuring SC injections.
- A proper skin fold is made with the thumb and index finger (possibly with the addition of the middle finger)
- Lifting the skin by using the whole hand risks lifting muscle with the SC tissue and can lead to IM injections.

